Heart failure progresses primarily through fibrosis and adverse remodeling as a result of cardiac injury or stress. ST2 is a biomarker that, unlike natriuretic peptides or troponin, uniquely reflects this pathway.
ST2 changes rapidly with the patient’s underlying condition. ST2 allows clinicians to identify patients at highest risk for an adverse event. And unlike natriuretic peptides, ST2 is not affected by confounding factors, i.e., age, BMI, and renal function. In short, ST2 helps clinicians provide focused, personalized care.
*ASPECT-PLUS Instructions For Use.
**CV is TOTAL CV at 32 ng/ml.